MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory fu...

Full description

Bibliographic Details
Main Authors: Sara Abdelfatah, Angela Berg, Qi Huang, Li Jun Yang, Sami Hamdoun, Anette Klinger, Henry J. Greten, Edmond Fleischer, Thorsten Berg, Vincent K.W. Wong, Thomas Efferth
Format: Article
Language:English
Published: Elsevier 2019-09-01
Series:Acta Pharmaceutica Sinica B
Online Access:http://www.sciencedirect.com/science/article/pii/S221138351830827X

Internet

http://www.sciencedirect.com/science/article/pii/S221138351830827X

Similar Items